The FDA has issued a drug safety communication about fluconazole: long-term use at high dosages (400 to 800 mg/d) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.1 This risk does not appear to be associated with a single, low dose (150 mg) of fluconazole to treat vaginal yeast infection (candidiasis).
The FDA has issued a drug safety communication about fluconazole: long-term use at high dosages (400 to 800 mg/d) may be associated with a rare and distinct set of birth defects in infants whose mothers were treated with the drug during the first trimester of pregnancy.1 This risk does not appear to be associated with a single, low dose (150 mg) of fluconazole to treat vaginal yeast infection (candidiasis).
For indications of fluconazole other than vaginal candidiasis, the pregnancy category for fluconazole has been changed from category C to category D, meaning that there is evidence of human fetal risk based on human data but the potential benefits from the use of the drug in pregnant women with serious or life-threatening conditions may be acceptable despite its risks. The pregnancy category for a single dose of 150 mg of fluconazole for vaginal candidiasis remains category C.
Features prominent in infants with long-term exposure to high doses of fluconazole may include brachycephaly, abnormal facies, abnormal calvarial development, cleft palate, femoral bowing, thin ribs and long bones, arthrogryposis, and congenital heart disease.
More Information
Drug Information: Fluconazole
Reference
1. US Food and Drug Administration. FDA drug safety communication:
Use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants
. August 3, 2011. Accessed August 11, 2011.
Identifying gaps in syphilis treatment and prenatal care among pregnant individuals
May 17th 2024Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.
Read More
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Reducing multifetal pregnancy through publicly funded IVF programs
April 26th 2024Learn how a mandatory elective single-embryo transfer policy in publicly funded in vitro fertilization programs significantly decreases multifetal pregnancy rates, offering insights into mitigating risks in assisted reproduction.
Read More